Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W. et al.
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): A multicentre, open-label, randomised, non-inferiority, phase 3 trial.

Lancet Oncol 2018;
19: 660-71

Bibliographische Angaben herunterladen

Aufrufen in: